Summary Conflicting results have been published on the prognostic significance of t(14; 18) in follicular lymphoma: Yunis et al. (1989) reported that its presence indicated poor response to therapy and short survival, whereas Levine et al. (1988) showed no difference in prognosis between cases with and without the translocation. However these results were based on small series of cases and on follow-up periods (no longer than 7 years) which are relatively short for a disease with such a slow clinical evolution. Here we report an investigation of 70 cases of follicular lymphoma with long term follow-up data (up to 17 years). This series has been studied for the presence of the 14;18 translocation and for the expression of bcl-2 protein. Our results show that there are no grounds for considering either the 14;18 translocation or the expression of the bcl-2 protein to be useful prognostic markers in clinical practice.
A controversial issue concerning the 14; 18 chromosomal translocation is whether its presence, in approximately 70% of cases of follicular lymphoma (Pezzella et al., 1990a) , has any prognostic significance. Conflicting results have been published: in 1989 Yunis et al. reported a series of 20 cases, analysed by cytogenetics and Southern blotting, in which the presence of the translocation was associated with a poor response to therapy and short survival, whereas in 1988 Levine et al. had showed no difference in survival between 30 patients with and without the translocation detected cytogenetically. However these two studies were based on small numbers of patients and follow-up periods of no longer than 84 months.
The availability of monoclonal antibodies against bcl-2 protein (Pezzella et al., 1990b) which work on paraffinembedded lymph node biopsies (Gaulard et al., 1991) , and the possibility of detecting bcl-2 rearrangement in the same type of material using the polymerase chain reaction (Pezzella et al., 1990a) 
Immunohistochemistry
Immunohistological analysis for bcl-2 was performed on cryostat or paraffin sections using the APAAP method (Cordell et al., 1984) .
Southern blotting and polymerase chain reaction Southern blotting for detection of rearrangement in the major, the minor and the 5' breakpoint regions of the bcl-2 gene was performed as described (Pezzella et al., 1990a; Tsujimoto et al., 1987) .
PCR for the detection of rearrangements in major and the minor breakpoint regions was performed as reported previously (Pezzella et al., 1990a) . A 250 bp fragment of P-globin gene was amplified as a positive control.
Statistical analysis
Actuarial survival curves were plotted using the method of Kaplan and Meier (1958) , with statistical significance calculated using the Logrank test (Peto et al., 1977) and the hazard ratio and its confidence interval as described by Altman (1991) . Homogeneity of age in the different groups was assessed by calculating the value of F with one-way analysis of variances (Armitage & Berry, 1987) .
Results
The survival curve of the whole patient population is shown in Figure 1 . Two patterns of staining were observed:
(1) In 55 cases the great majority of neoplastic cells were bcl-2 positive. bcl-2 rearrangement was found in 24 out of 51 cases on which PCR and/or Southern blotting could be performed. (2) In nine cases the neoplastic follicles were bcl-2 negative. PCR and/or Southern blotting were negative in each of the six cases which could be analysed. It is worthy of note (as shown in Table I ) that the last category (i.e. bcl-2 negative lymphoma) predominated (55%) in group D (large cell type) whereas it accounted for only 6% and 7.5% of cases respectively in groups B and C.
Survival curves for each group of patients showed close overlap with no statistically significant differences (Figure 2 ). There were no differences in clinical and histological features between cases with and without bcl-2 rearrangement (Table II) . Survival curves for these patients were similar, with no significant differences between them (Figure 3 ). The hazard ratio was 2.08 with a confidence interval at 95% from 0.83 to 6.81. 
Discussion
A first problem in the present study is that the evaluation of prognosis could have been affected by the heterogeneity of treatment received by patients because of their provenance from two different centres over a period of 30 years. However the actuarial survival curve for our series (Figure 1) is consistent with the literature (The non-Hodgkin's lymphoma pathologic classification project, 1982) indicating that the validity of our observations is not altered by such a problem.
Our results are at variance with the findings of Yunis et al. (1989) . These authors investigated a series of 20 follicular lymphomas and concluded that cases with 14; 18 translocation had a significantly worse prognosis. We have been unable to confirm this finding, either in relation to rearrangement of the bcl-2 gene or to bcl-2 protein expression. The series of Yunis et al. was A similar criticism could be raised against the current study since although the overall number of cases (70) is considerably higher than in previously reports, the number negative for bcl-2 protein expression or not rearranged at the bcl-2 gene, is relatively low. However the statistical analysis of the confidence limits of the hazard ratio in this study, especially for the bcl-2 protein expression (from 0.4 to 2.6 at 95%) indicates that a dramatic difference between the positive and negative cases can be excluded.
The presence of abnormal levels of bcl-2 is not sufficient for the neoplastic transformation of cell lines (Vaux et al., 1988) ; this finding is supported by the identification of t(14;18) in reactive lymph nodes (Limpens et al., 1990) . If one accepts that bcl-2 deregulation gives a limited growth advantage, that it plays a role early in the neoplastic process, and that further events are likely to be needed for the evolution of the neoplasia, then it is perhaps not surprising that neither the 14;18 translocation nor bcl-2 expression are closely linked with the rate of progression of the disease.
Indeed it is possible, as recently suggested (Yonish-Rouach et al., 1991) that alteration of other genes, that are also involved in the mediation of apoptosis, could produce similar effects in the absence of bcl-2 deregulation. This could then lead to bcl-2 negative lymphomas with a biological and clinical behaviour similar to that observed in the bcl-2 positive ones.
In conclusion, whatever the roles of bcl-2 gene rearrangement and/or protein expression may be in the development of follicular lymphoma, they show no obvious correlation with clinical behaviour.
